Research shows semaglutide — commonly sold as Ozempic or Wegovy — can improve kidney function and survival rates for people ...

When the results of the SELECT trial landed in the New England Journal of Medicine in November 2023, they confirmed what ...

A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart ...

Clinicians gathered in Houston, Texas, to examine how newer drug options are reshaping cardiometabolic care and how ...

Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual ...

Adding to a growing body of research about the related health benefits of diabetes weight-loss drugs, an August 31 study in the Journal of the American Medical Association found that semaglutide and ...

Researchers report that the weight loss drugs semaglutide and tirzepatide can reduce the risk of hospitalization and death by 40% in people with a common type of heart failure. Experts say this large ...

MADRID -- Digitoxin added to guideline-directed medical therapy improved outcomes among patients with heart failure and reduced ejection fraction (HFrEF), the DIGIT-HF trial showed. The cardiac ...

ROCKVILLE, Md., Aug. 14 -- The makers of rosiglitazone (Avandia) and pioglitazone (Actos), have agreed to add a black box warning to the type 2 diabetes drugs' labels about an increased risk of heart ...

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In a recent study, his group and ...

A massive international study could upend 40 years of heart attack treatment. Researchers found that beta blockers—routinely prescribed after uncomplicated heart attacks—offered no real benefit for ...